As researchers keep looking for ways to deescalate treatment in HER2-positive breast cancer, a trial from China looked at a chemotherapy-free regimen with endocrine therapy, a CDK4/6 inhibitor, and ...

The firm will test gedatolisib as a first-line treatment in patients with HR-positive, HER2-negative advanced breast cancer who are endocrine therapy resistant.

No one wants to hear the words: "You have cancer." But about 1 in 8 American women will learn they have breast cancer, according to the Centers for Disease Control and Prevention. "Breast ...

A reproductive endocrinologist was found liable in a medical malpractice lawsuit after failing to diagnose a patient with ...

Michael Hassett, MD, MPH, Dana-Farber Cancer Institute, reflects on the impact of HER2 identification on the breast cancer ...

On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second ...

A local breast cancer survivor is now sharing her story, urging patients like her, to be confident in their plan, by receiving a “second opinion” from a professional.

As first-line treatments in metastatic HER2-positive breast cancer evolve, the firm expects its HER2 targeted therapies to remain integral to growth.

Precision-targeted therapy via antibody drugs has become central to the field of cancer immunotherapy. Monoclonal antibodies ...

Swiss pharma giant Roche Holding AG (RHHBY) reported sales of CHF 30.9 billion for the first half of 2025, up 4% year over ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...